Guild working on hep C cash flow problems

The Guild says it is continuing to work with stakeholders following the revelation that a large minority of pharmacies may not supply the expensive, newly-listed Hepatitis C drugs to patients for economic reasons.Last week the AJP reported on the results of a reader survey which found that 22% of respondents were not providing the drugs